New immune cell therapy for blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new type of CAR-T cell therapy designed to treat certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard treatment. The cells are enhanced with IL-15 to help them work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 15 to 80 years old.
- You have a type of blood cancer that is positive for CD19, CD22, or BCMA and has come back after treatment or not responded to standard therapy.
- Your heart, liver, and kidney function are within certain safe limits.
- You have an estimated life expectancy of at least 12 weeks.
- You are not pregnant or breastfeeding and agree to avoid pregnancy for 2 years after treatment.
- You do not have serious active infections or other unstable medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of immune therapy called CAR-T cells, which are made from your own blood cells to find and attack cancer. It is for adults with leukemia or lymphoma that has come back or is hard to treat.
This trial tests a new immune cell treatment (called CAR-T) that has been modified to help the cells stay active longer. It is designed for adults with B-cell leukemia or lymphoma who cannot tolerate strong chemotherapy, offering a potentially gentler option.
This study tests a new type of cell therapy that engineers your own immune cells to find and attack cancer cells that have either CD19 or CD20 markers. It is for people with B-cell lymphomas or leukemias that have come back or not responded to other treatments.
This study tests a personalized cell treatment called CAR-T for people whose blood cancer (like lymphoma, leukemia, or chronic lymphocytic leukemia) has come back or not gotten better after standard treatment. The therapy uses your own immune cells, modified in a lab, to find and fight the cancer.
This trial tests an experimental therapy called CT1195E, a type of 'living drug' made from your own immune cells to fight B-cell cancers that have returned or not responded to standard care. It's a phase 1 study, which means the main goal is to find a safe and effective dose, but you may benefit from the treatment.
This trial tests a personalized cancer treatment called CAR-T therapy. It uses your own immune cells, which are modified in a lab to fight your specific type of blood cancer, and then given back to you. The goal is to see if this treatment is safe and feasible when produced locally.
Hear when a new Acute Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.